{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T01:37:47Z","timestamp":1763429867038,"version":"3.37.3"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015516","name":"Revance Therapeutics, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015516","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Evidence Scientific Solutions"},{"name":"Revance Therapeutics, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>\u00a0<\/jats:title>\n                  <jats:p>DaxibotulinumtoxinA-lanm for injection (DAXI), a novel botulinum toxin type A formulation, contains a purified 150-kD core neurotoxin (daxibotulinumtoxinA) and proprietary stabilizing peptide (RTP004), and is approved for glabellar line treatment. As with any biologic product, DAXI may potentially be immunogenic and elicit unwanted antibody formation, possibly resulting in partial or complete treatment failure. The immunogenicity of DAXI was assessed in 2 double-blind, placebo-controlled, single-dose studies and an open-label safety study of up to 3 repeat treatments. Of the 2737 evaluable patients, none developed neutralizing antibodies to daxibotulinumtoxinA and 0.8% developed treatment-related nonneutralizing anti\u2013daxibotulinumtoxinA-binding antibodies. Of evaluable patients exposed to RTP004 with either DAXI or placebo, 1.3% developed treatment-related anti\u2013RTP004-binding antibodies, which were mostly transient. No patient developed binding antibodies to both daxibotulinumtoxinA and RTP004. All patients with treatment-related binding antibodies to daxibotulinumtoxinA or RTP004 achieved a clinical response (none or mild glabellar line severity) at Week 4 following each DAXI treatment cycle. The duration of clinical response was not different between treatment cycles when antibodies were detected vs when they were absent. Although the analysis population was small compared to the number of patients likely to receive repeated treatment in clinical practice, these results suggest that DAXI administration at the approved glabellar lines dose has low immunogenic potential and that nonneutralizing antibodies to daxibotulinumtoxinA or RTP004 occur infrequently and often transiently, and have no impact on clinical efficacy, safety, or duration of action. Real-world data encompassing larger numbers of patients is needed to substantiate these results.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Level of Evidence: 3<\/jats:title>\n                  <jats:p\/>\n               <\/jats:sec>","DOI":"10.1093\/asj\/sjad101","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T08:45:37Z","timestamp":1681375537000},"page":"1189-1193","source":"Crossref","is-referenced-by-count":5,"title":["Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines"],"prefix":"10.1093","volume":"43","author":[{"given":"Shannon","family":"Humphrey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey S","family":"Dover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald R","family":"Bowsher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Clancy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregg","family":"Prawdzik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conor J","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"issue":"1","key":"2023091517500987800_sjad101-B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40268-014-0077-1","article-title":"Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products","volume":"15","author":"Frevert","year":"2015","journal-title":"Drugs R D"},{"issue":"2","key":"2023091517500987800_sjad101-B2","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1124\/pr.116.012658","article-title":"Botulinum neurotoxins: biology, pharmacology, and toxicology","volume":"69","author":"Pirazzini","year":"2017","journal-title":"Pharmacol Rev"},{"issue":"7","key":"2023091517500987800_sjad101-B3","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.imbio.2010.12.009","article-title":"Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies","volume":"216","author":"Atassi","year":"2011","journal-title":"Immunobiology"},{"issue":"1","key":"2023091517500987800_sjad101-B4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3390\/toxins15010060","article-title":"Clinical immunogenicity of daxibotulinumtoxinA for injection in glabellar lines: pooled data from the SAKURA phase 3 trials","volume":"15","author":"Gallagher","year":"2023","journal-title":"Toxins (Basel)"},{"issue":"1","key":"2023091517500987800_sjad101-B5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/PRS.0000000000006327","article-title":"DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)","volume":"145","author":"Carruthers","year":"2020","journal-title":"Plast Reconstr Surg"},{"issue":"1","key":"2023091517500987800_sjad101-B6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/dss.0000000000002531","article-title":"DaxibotulinumtoxinA for injection for the treatment of glabellar lines: efficacy results from SAKURA 3, a large, open-label, phase 3 safety study","volume":"47","author":"Fabi","year":"2021","journal-title":"Dermatol Surg"},{"issue":"1","key":"2023091517500987800_sjad101-B7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/dss.0000000000002463","article-title":"A large, open-label, phase 3 safety study of daxibotulinumtoxinA for injection in glabellar lines: a focus on safety from the SAKURA 3 study","volume":"47","author":"Green","year":"2021","journal-title":"Dermatol Surg"},{"issue":"1","key":"2023091517500987800_sjad101-B8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/asj\/sjab058","article-title":"Immunogenicity to botulinum toxin type A: a systematic review with meta-analysis across therapeutic indications","volume":"42","author":"Rahman","year":"2022","journal-title":"Aesthet Surg J"},{"issue":"9","key":"2023091517500987800_sjad101-B9","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3390\/toxins11090491","article-title":"Immunogenicity associated with botulinum toxin treatment","volume":"11","author":"Bellows","year":"2019","journal-title":"Toxins (Basel)"},{"issue":"2","key":"2023091517500987800_sjad101-B10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00702-012-0893-9","article-title":"Immunogenicity of botulinum toxins","volume":"120","author":"Naumann","year":"2013","journal-title":"J Neural Transm (Vienna)"},{"issue":"12","key":"2023091517500987800_sjad101-B11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3390\/toxins10120535","article-title":"AbobotulinumtoxinA (Dysport\u00ae), OnabotulinumtoxinA (Botox\u00ae), and IncobotulinumtoxinA (Xeomin\u00ae) neurotoxin content and potential implications for duration of response in patients","volume":"10","author":"Field","year":"2018","journal-title":"Toxins (Basel)"},{"issue":"1","key":"2023091517500987800_sjad101-B12","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1212\/wnl.0000000000006688","article-title":"High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy","volume":"92","author":"Albrecht","year":"2019","journal-title":"Neurology"},{"issue":"4","key":"2023091517500987800_sjad101-B13","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jaad.2019.06.1313","article-title":"DaxibotulinumtoxinA for injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)","volume":"82","author":"Bertucci","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"2023091517500987800_sjad101-B14","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1212\/01.wnl.0000183055.81056.5c","article-title":"Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia","volume":"65","author":"Comella","year":"2005","journal-title":"Neurology"},{"author":"Allergan","key":"2023091517500987800_sjad101-B15"},{"author":"Ipsen","key":"2023091517500987800_sjad101-B16"},{"issue":"18","key":"2023091517500987800_sjad101-B17","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1007\/s40265-021-01631-w","article-title":"Overview of DaxibotulinumtoxinA for injection: a novel formulation of botulinum toxin type A","volume":"81","author":"Solish","year":"2021","journal-title":"Drugs"},{"key":"2023091517500987800_sjad101-B18","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1002\/mds.20020","article-title":"Basic immunological aspects of botulinum toxin therapy","volume":"19","author":"Atassi","year":"2004","journal-title":"Mov Disord"},{"key":"2023091517500987800_sjad101-B19","doi-asserted-by":"publisher","first-page":"vi3","DOI":"10.1093\/ndt\/gfh1092","article-title":"Factors influencing the immunogenicity of therapeutic proteins","volume":"20","author":"Schellekens","year":"2005","journal-title":"Nephrol Dial Transplant"}],"container-title":["Aesthetic Surgery Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/asj\/advance-article-pdf\/doi\/10.1093\/asj\/sjad101\/50375364\/sjad101.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/article-pdf\/43\/10\/1189\/51605193\/sjad101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/article-pdf\/43\/10\/1189\/51605193\/sjad101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T17:51:14Z","timestamp":1694800274000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/asj\/article\/43\/10\/1189\/7116671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":19,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,4,13]]},"published-print":{"date-parts":[[2023,9,14]]}},"URL":"https:\/\/doi.org\/10.1093\/asj\/sjad101","relation":{},"ISSN":["1090-820X","1527-330X"],"issn-type":[{"type":"print","value":"1090-820X"},{"type":"electronic","value":"1527-330X"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,4,13]]}}}